Browsing by Author "Servitja Tormo, Sonia"

Sort by: Order: Results:

  • Pineda-Moncusí, Marta; Servitja Tormo, Sonia; Tusquets Trias de Bes, Ignacio; Díez Pérez, Adolfo; Rial, Abora; Cos, Maria Lourdes; Campodarve, Isabel; Rodriguez-Morera, Jaime; Garcia Giralt, Natàlia; Nogués Solan, Francesc Xavier (Springer, 2019)
    PURPOSE: The most frequent adverse effects of aromatase inhibitors (AI) are arthralgia and bone loss induction. These reduce the quality of life of patients and their adherence to the treatment. This study evaluates the ...
  • Posso, Margarita; Corominas Torres, Josep Maria; Serrano, Laia; Román, Marta; Torá Rocamora, Isabel, 1979-; Domingo, Laia; Romero, Anabel; Quintana, María Jesús; Vernet-Tomás, Maria; Baré, Marisa; Vidal, Carmen; Sánchez, Mar; Saladié, Francina; Natal, Carmen; Ferrer, Joana; Servitja Tormo, Sonia; Sala, Maria; Castells, Xavier; BELE Study Group (Wiley, 2017)
    Women with benign breast diseases (BBD) have a high risk of breast cancer. However, no biomarkers have been clearly established to predict cancer in these women. Our aim was to explore whether estrogen receptor (ER), ...
  • Pineda-Moncusí, Marta; Servitja Tormo, Sonia; Casamayor, Guillem; Cos, Maria Lourdes; Rial, Abora; Rodriguez-Morera, Jaime; Tusquets Trias de Bes, Ignacio; Díez Pérez, Adolfo; Garcia Giralt, Natàlia; Nogués Solan, Francesc Xavier (Elsevier, 2018)
    Breast cancer patients treated with aromatase inhibitors (AIs) experience increased bone loss during their treatment. However, there is little information about bone mineral density (BMD) after completing AI-treatment. The ...
  • Román, Marta; Caicoya, Martin; Espinàs, Josep Alfons; Sala Serra, Maria; Torá Rocamora, Isabel, 1979-; Quinta, Maria J.; Vernet-Tomás, Maria; Saladié, Francina; Romero, Anabel; Sánchez, Mar; Baré, Marisa; Vidal, Carmen; Servitja Tormo, Sonia; Natal, Carmen; Corominas Torres, Josep Maria; Ferrer, Joana; Rodríguez Arana, Ana Maria; Castells, Xavier; BELE Study Group (Wiley-Blackwell, 2018)
    Women with a benign breast disease (BBD) have an increased risk of subsequent breast carcinoma. Information is scarce regarding the characteristics of breast carcinomas diagnosed after a BBD. Our aim was to point out the ...
  • Sabbaghi Mehrjardi, Mohammad Ali; Gil Gómez, Gabriel; Guardia Laguarta, Cristina; Servitja Tormo, Sonia; Arpí Llucià, Oriol; Menendez Romero, Silvia; Arumí, Montserrat; Serrano, Laia; Salido Galeote, Marta; Muntasell i Castellví, Aura, 1972-; Martínez-García, Maria; Tusquets Trias de Bes, Ignacio; Rovira Guerín, Ana; Albanell Mestres, Joan (American Association for Cancer Research (AACR), 2017)
    Purpose: Trastuzumab-emtansine (T-DM1) is a standard treatment in advanced HER2-positive breast cancer. However, resistance inevitably occurs. We aimed to identify mechanisms of acquired T-DM1 resistance.Experimental Design: ...
  • Dalmases Massegú, Alba, 1982-; González González, Irene; Menendez Romero, Silvia; Arpí Llucià, Oriol; Corominas Torres, Josep Maria; Servitja Tormo, Sonia; Tusquets Trias de Bes, Ignacio; Chamizo, Cristina; Rincón, Raúl; Espinosa Blay, Lluís; Bigas Salvans, Anna; Eroles, Pilar; Furriol, Jessica; Lluch, Ana; Rovira Guerín, Ana; Albanell Mestres, Joan; Rojo, Federico (Impact Journals, 2014)
    NF-кB has been linked to doxorubicin resistance in breast cancer patients. NF-кB nuclear translocation and DNA binding in doxorubicin treated-breast cancer cells have been extensively examined; however its functional ...
  • Vazquez, Juan Carlos; Antolin, Silvia; Ruiz-Borrego, Manuel; Servitja Tormo, Sonia; Alba, Emilio; Barnadas, Agustí; Lluch, Ana; Martín, Miguel; Rodríguez-Lescure, Álvaro; Solà, Ivan; Bonfill, Xavier; Urrutia, Gerard; Sanchez-Rovira, Pedro (Springer, 2022)
    Background: we aimed to determine the effect of dual anti-HER2 blockade compared to monotherapy on clinically important outcomes. Methods: we carried out a systematic review updated until July 2022. The outcomes included ...
  • Rodríguez Sanz, Maria, 1984-; Prieto-Alhambra, Daniel; Servitja Tormo, Sonia; Garcia Giralt, Natàlia; Garrigós, Laia; Albanell Mestres, Joan; Martinez-García, Maria; González, I.; Martos, Tamara; Díez Pérez, Adolfo; Tusquets Trias de Bes, Ignacio; Nogués Solan, Francesc Xavier (Sociedad Española de Investigación Ósea y del Metabolismo Mineral, 2015)
    Objetivos: El objetivo del estudio fue analizar los cambios en la densidad mineral ósea (DMO) a lo largo del tratamiento con inhibidores de aromatasa (IA) en la práctica clínica y evaluar la asociación entre el gen CYP11A1 ...
  • Torregrosa-Maicas, Maria Dolores; Barco Berrón, Sonia del; Cotes Sanchís, Almudena; Lema Roso, L.; Servitja Tormo, Sonia; Gironés i Sarrió, Regina (Springer, 2022)
    Most patients diagnosed with luminal metastatic breast cancer (MBC) who are seen in oncology consultations are elderly. MBC in elderly patients is characterized by a higher percentage of hormone receptor (HR) expression ...
  • Pineda-Moncusí, Marta; Garcia Giralt, Natàlia; Díez Pérez, Adolfo; Servitja Tormo, Sonia; Tusquets Trias de Bes, Ignacio; Prieto-Alhambra, Daniel; Nogués Solan, Francesc Xavier (Wiley, 2020)
    Aromatase inhibitors have been associated with accelerated bone loss and an increased risk of osteoporotic fractures. Currently, bisphosphonates are recommended to reduce fracture risk in these patients. The aim of this ...
  • Muntasell i Castellví, Aura, 1972-; Cabo, Mariona, 1991-; Servitja Tormo, Sonia; Tusquets Trias de Bes, Ignacio; Martínez-García, Maria; Rovira Guerín, Ana; Rojo, Federico; Albanell Mestres, Joan; López-Botet, Miguel (Frontiers, 2017)
    Overexpression of the human epidermal growth factor receptor 2 (HER2) defines a subgroup of breast tumors with aggressive behavior. The addition of HER2-targeted antibodies (i.e., trastuzumab, pertuzumab) to chemotherapy ...
  • Pérez-Núñez, Iván; Rozalén, Catalina; Palomeque, José Ángel; Sangrador, Irene; Dalmau, Mariona; Comerma Blesa, Laura, 1983-; Hernández Prat, Anna, 1984-; Casadevall Aguilar, David; Menendez Romero, Silvia; Liu, Dan; Berenguer De Felipe, Jordi; Peña Arranz, Raúl, 1976-; Montañés, José Carlos; Albà Soler, Mar; Bonnin, Sarah; Ponomarenko, Julia; Servitja Tormo, Sonia; Arribas, Joaquín; Albanell Mestres, Joan; Celià-Terrassa, Toni (Nature Research, 2022)
    Ligand-dependent corepressor (LCOR) mediates normal and malignant breast stem cell differentiation. Cancer stem cells (CSCs) generate phenotypic heterogeneity and drive therapy resistance, yet their role in immunotherapy ...
  • Martín, Miguel; Servitja Tormo, Sonia; Aguiar-Bujanda, David (Springer, 2023)
    Purpose: The monarchE trial showed that the addition of abemaciclib improves efficacy in patients with high-risk early breast cancer (EBC). We analyzed the long-term outcomes of a population similar to the monarchE trial ...
  • Santana-Hernández, Sara; Suárez Olmos, Jesús; Servitja Tormo, Sonia; Berenguer-Molins, Pau; Costa García, Marcel, 1989-; Comerma Blesa, Laura, 1983-; Rea, Anna; Perera Bel, Júlia; Menendez Romero, Silvia; Arpí Llucià, Oriol; Bermejo, Begoña; Martínez, María Teresa; Cejalvo, Juan Miguel; Comino-Méndez, Iñaki; Pascual, Javier; Alba, Emilio; López-Botet, M. (Miguel); Rojo, Federico; Rovira, Ana; Albanell Mestres, Joan; Muntasell i Castellví, Aura, 1972- (BioMed Central, 2024)
    Background: The variability in responses to neoadjuvant treatment with anti-HER2 antibodies prompts to personalized clinical management and the development of innovative treatment strategies. Tumor-infiltrating Natural ...
  • Manso, Luis; Servitja Tormo, Sonia; Moreno, Fernando (Elsevier, 2020)
    Background: This study evaluated efficacy and safety of palbociclib, a CDK4/6 inhibitor, in heavily-pretreated hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast ...
  • Ayala de la Peña, F.; Andrés, Raquel; Garcia-Saenz, José Angel; Manso, Luis; Margeli, M. E.; Dalmau, M. E.; Pernas, S.; Prat, Aleix; Servitja Tormo, Sonia; Ciruelos, Eva (SpringerOpen, 2019)
    Breast cancer is the most common cancer in women in our country and it is usually diagnosed in the early and potentially curable stages. Nevertheless, around 20-30% of patients will relapse despite appropriate locoregional ...
  • Garcia-Saenz, José Angel; Bermejo, Begoña; Estevez, L. G.; Palomo, A. G.; González-Farré, X.; Margeli, M. E.; Pernas, S.; Servitja Tormo, Sonia; Rodríguez, C. A.; Ciruelos, Eva (Springer, 2015)
    Breast cancer is a major public health problem. Despite remarkable advances in early diagnosis and treatment, one in three women may have metastases since diagnosis. Better understanding of prognostic and predictive factors ...
  • Martínez-García, Maria; Servitja Tormo, Sonia; Vilariño Quintela, Noelia; Arance Fernández, Ana; Berrocal Jaime, Alfonso; Cantos Sánchez de Ibargüen, Blanca; Barco Berrón, Sonia del; García Campelo, Rosario; Gironés i Sarrió, Regina; Sepúlveda-Sánchez, Juan Manuel (Springer, 2022)
    Central nervous system (CNS) dissemination is a severe complication in cancer and a leading cause of cancer-related mortality. Brain metastases (BMs) are the most common types of malignant intracranial tumors and are ...
  • Rodríguez Sanz, Maria, 1984-; Pineda-Moncusí, Marta; Servitja Tormo, Sonia; Garcia Giralt, Natàlia; Martos, Tamara; Tusquets Trias de Bes, Ignacio; Martínez-García, Maria; Rodriguez-Morera, Jaime; Díez Pérez, Adolfo; Albanell Mestres, Joan; Nogués Solan, Francesc Xavier (Elsevier, 2016)
    INTRODUCTION: Patients with breast cancer under aromatase inhibitor (AI) treatment often develop osteoporosis and their average bone loss rate is twice that of natural reduction during menopause, increasing fracture risk. ...
  • Pineda-Moncusí, Marta; Garcia Giralt, Natàlia; Díez Pérez, Adolfo; Tusquets Trias de Bes, Ignacio; Servitja Tormo, Sonia; Albanell Mestres, Joan; Prieto-Alhambra, Daniel; Nogués Solan, Francesc Xavier (SAGE Publications, 2020)
    Background: Tamoxifen (TAM) and aromatase inhibitor (AI) therapies have been associated with increased risk of thromboembolic and cardiovascular events, respectively, in addition to other side effects. This study analysed ...

Search DSpace

Browse

My Account

In collaboration with Compliant to Partaking